Overcoming Challenges of Classical TCR Targets with Novel, MR1 Cancer-Specific TCRs

Time: 9:30 am
day: Day One


  • Overview of the advances and potential patient benefit of TCR-based therapies
  • Highlight challenges associated with traditional TCR targets, such as HLA restriction and antigen expression
  • Introduce MR1 as an HLA-like target that appears to present cancerspecific ligands
  • Present data and potential high-level development plans for TCRtargeting of MR1 in cancer